Roundtable Discussion: Defining What Biopharma Needs from Raw Material Suppliers to Enable Scalable, Reliable CGT Manufacturing
- Aligning expectations on material quality, data transparency, and change control to reduce downstream risk
- Understanding where current supplier offerings fall short across development through commercial scale
- Defining what strong partnerships look like in practice, from early engagement to long-term collaboration